No Pain, Lots To Gain: Vertex Looks For Non-Opioid Drug Breakthrough

Vertex is closing in on annual revenues of $10bn from its cystic fibrosis drugs, but non-opioid pain therapy candidate VX-548 could open up a whole new blockbuster revenue stream if Phase III studies go to plan.